Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
140.97
+2.08 (1.50%)
At close: May 16, 2025, 4:00 PM
140.97
0.00 (0.00%)
After-hours: May 16, 2025, 7:00 PM EDT
CRL Market Cap
CRL has a market cap or net worth of $6.92 billion as of May 16, 2025. Its market cap has decreased by -41.12% in one year.
Market Cap
6.92B
Enterprise Value
9.68B
1-Year Change
-41.12%
Ranking
Category
Stock Price
$140.97
Market Cap Chart
Since June 23, 2000, CRL's market cap has increased from $226.30M to $6.92B, an increase of 2,959.59%. That is a compound annual growth rate of 14.72%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 15, 2025 | 6.82B | -27.73% |
Dec 31, 2024 | 9.44B | -22.16% |
Dec 29, 2023 | 12.13B | 9.38% |
Dec 30, 2022 | 11.09B | -41.69% |
Dec 31, 2021 | 19.01B | 52.98% |
Dec 31, 2020 | 12.43B | 66.59% |
Dec 31, 2019 | 7.46B | 37.05% |
Dec 31, 2018 | 5.44B | 5.01% |
Dec 29, 2017 | 5.18B | 43.75% |
Dec 30, 2016 | 3.61B | -3.79% |
Dec 31, 2015 | 3.75B | 25.52% |
Dec 31, 2014 | 2.99B | 17.00% |
Dec 31, 2013 | 2.55B | 40.28% |
Dec 31, 2012 | 1.82B | 34.64% |
Dec 30, 2011 | 1.35B | -34.13% |
Dec 31, 2010 | 2.05B | -7.60% |
Dec 31, 2009 | 2.22B | 25.20% |
Dec 31, 2008 | 1.77B | -60.32% |
Dec 31, 2007 | 4.47B | 54.46% |
Dec 29, 2006 | 2.89B | -5.57% |
Dec 30, 2005 | 3.06B | 2.77% |
Dec 31, 2004 | 2.98B | 89.75% |
Dec 31, 2003 | 1.57B | -9.52% |
Dec 31, 2002 | 1.74B | 17.55% |
Dec 31, 2001 | 1.48B | 50.25% |
View and export this data all the way back to 2000.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 649.98B |
Johnson & Johnson | 352.21B |
AbbVie | 314.51B |
Novo Nordisk | 288.64B |
UnitedHealth Group | 282.07B |
Abbott Laboratories | 223.40B |
Novartis AG | 209.81B |
AstraZeneca | 209.59B |